Evidence map›Paper›PMID 33200797›Full record

ArticleMolecular medicine reports2021

miR‑140‑5p inhibits the proliferation of multiple myeloma cells by targeting VEGFA.

Min Liu, Huimin Liu, Jing Zhou, Zhuojun Yu

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Min Liu *Department of Hematology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
Huimin Liu *Department of Hematology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
Jing ZhouDepartment of Hematology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
Zhuojun YuDepartment of Hematology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China.
Jingzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miR)‑140‑5p is associated with the growth and metastasis of various tumor cell types, yet its role in multiple myeloma (MM) remains unclear. Therefore, the present study aimed to investigate the regulatory effect of miR‑140‑5p on MM. Reverse transcription‑quantitative PCR analysis demonstrated that miR‑140‑5p was downregulated in MM cell lines, particularly in U266 and RPMI 8226 cells. A Cell Counting Kit‑8, wound healing and Transwell assays, as well as flow cytometry indicated that a miR‑140‑5p mimic could suppress cell viability, migration and invasion. In addition, the mimic promoted apoptosis of U266 and RPMI 8226 cells. Western blot data demonstrated that transfection with miR‑140‑5p mimic significantly reduced the expression levels of Ki‑67, cyclin D1, vimentin, Snail, matrix metalloproteinase (MMP)‑2 and MMP‑3. Moreover, as predicted by TargetScan7.2 and verified by luciferase activity assay, it was demonstrated that vascular endothelial growth factor A (VEGFA) was targeted by miR‑140‑5p. Further experiments indicated that VEGFA overexpression promoted cell viability, migration and invasion and suppressed apoptosis of MM cells, and that the miR‑140‑5p mimic partially reversed the effects of VEGFA overexpression. Therefore, miR‑140‑5p suppressed MM progression by targeting VEGFA. The present findings provide insight into potential therapeutic strategies for the treatment of MM.

Indexed as

ApoptosisCell Line, TumorCell MovementCell ProliferationCell SurvivalDown-RegulationFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHealthy VolunteersHumansMaleMicroRNAsMiddle AgedMultiple MyelomaPlasma CellsMicroRNAsMirn140 microRNA, humanVascular Endothelial Growth Factor AVEGFA protein, humaninvasionmigrationmiR‑140‑5pmultiple myelomaproliferationVEGFA

Identifiers

PMID33200797
PMCPMC7706004
OpenAlexW3099337160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.